Remacemide: current status and clinical applications

Bibliography

• LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl. J. Med. (1994) 330:613–622.
   PubMed Web of Science ®Google Scholar
• •Excellent introduction to the theory of excitatory neurotoxicity.
   Google Scholar
• THOMAS RJ: Excitatory amino acids in health and disease. J. Am. Geriatr. Soc. (1995) 43:1279–1289.
   PubMed Web of Science ®Google Scholar
• ROGAWSKI MA: Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. (1993) 14:325–331.
   PubMed Web of Science ®Google Scholar
• LOSCHER W: Basic aspects of epilepsy. Curr. Opin. Neurol Neurosurg. (1993) 6:223–232.
   PubMedGoogle Scholar
• MELDRUM BS: Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res. (1992) 12:189–196.
   PubMed Web of Science ®Google Scholar
• LEE J-M, ZIPFEL GJ, CHOI DW: The changing landscape of ischaemic brain injury mechanisms. Nature (1999) 399 (Suppl.) :A7–A14.
   Google Scholar
• •Comprehensive update on glutamergic mechanisms of neurotoxicity.
   Google Scholar
• DUNNETT SB, BJORKLUND A: Prospects for new restorative and neuroprotective treatments in Parkin-son's disease. Nature (1999) 399 (Suppl.):A32–A39.
   Google Scholar
• ALBIN RL, GREENAMYRE JT: Alternative excitotoxic hypotheses. Neurology (1992) 42:733–738.
   PubMed Web of Science ®Google Scholar
• PORTER RHP, GREENAMYRE JT: Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. (1995) 64:614–623.
   PubMed Web of Science ®Google Scholar
• WILLETTS J, BALSTER RL, LEANDER JD: The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. (1990) 11:423–428.
   PubMed Web of Science ®Google Scholar
• OLNEY JW, LABRUYERE J, PRICE MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science (1989) 244:1360–1362.
   PubMed Web of Science ®Google Scholar
• MCNAMARA JO, RUSSELL RD, RIGSBEE L, BONHAUS DW: Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology (1988) 27:563–568.
   PubMed Web of Science ®Google Scholar
• CLARK B, HUTCHISON JB, JAMIESON V, JONES T, PALMER GC, SCHEYER RD: Remacemide hydrochloride. In: Anti-epileptic Drugs, Fourth Edition. Levy RH, Mattson RH, Meldrum BS (Eds.) Raven Press Ltd., New York, USA (1995):1035–1044.
   Google Scholar
• ROGAWSKI MA, PORTER RJ: Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. (1990) 42:223–286.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: The impact of remacemide hydrochloride on levodopa concentrations in Parkin-son's disease. Clin. Neuropharmacol (1999) 22:220–225.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN, SANDER JWAS: Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Safety (1994) 11:37–67.
   Google Scholar
• STABLES JP, BIALER M, JOHANNESSEN SI et al.: Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res. (1995) 22:235–246.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAM S, DONEVAN SD, ROGAWSKI MA: Blockof the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J. Pharmacol. Exp. Ther. (1996) 276:161–168.
   PubMed Web of Science ®Google Scholar
• LINDSTROM P, BEN MENACHEM E, SODERFELDT B: CSF concentrations of remacemide and its desglycinyl metabolite in a double blind placebo controlled study of 3 doses (300, 600, 1200 mg) remacemide hydrochlo-ride as add-on therapy in patients with refractory epilepsy. Epilepsia (1996) 37\(Suppl. 5):166.
   Google Scholar
• PALMER GC, MURRAY RJ, WILSON TCM et al.: Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res. (1992) 12:9–20.
   PubMed Web of Science ®Google Scholar
• •Thorough review of the pharmacokinetics of remacemide.
   Google Scholar
• RILEY RJ, LAMBERT C, COOPER AE et al.: Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Drug Metab. Dispos. (1995) 23:922–928.
   PubMed Web of Science ®Google Scholar
• LEACH JP, BLACKLAW J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Mutual interaction between remace-mide hydrochloride and carbamazepine: two drugs with active metabolites. Epilepsia (1996) 37:1100–1106.
   PubMed Web of Science ®Google Scholar
• LEACH JP, GIRVAN J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Mutual interaction between remacemide hydrochloride and phenytoin. Epilepsy Res. (1997) 26:381–388.
   PubMed Web of Science ®Google Scholar
• LEACH JP, GIRVAN J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Seizure (1997) 6:179–184.
   PubMedGoogle Scholar
• BLAKEY GE, LOCKTON JA, ROLAN IP: The effect of lamotrigine on the disposition of remacemide hydrochloride. Epilepsia (1999) 40\(Suppl. 2)251.
   Google Scholar
• MAWER GE, PLEUVRY BJ: Interactions involving newantiepileptic drugs. Pharmacol Ther. (1995) 68:209–231.
   PubMed Web of Science ®Google Scholar
• HEYN H, MCCARTHY DJ, CURRY SH, EISMAN MS, ANDERSMW: Brain uptake and biotransformation of remace-mide hydrochloride, a novel anticonvulsant. Drug Metab. Dispos. (1994) 22:443–446.
   PubMed Web of Science ®Google Scholar
• CURRY S, MCCARTHY DJ, CASE KR, EISMAN MS, MARLER MR, MAHMOOD NA: Disposition and pharmacokinetics of remacemide hydrochloride in male Sprague-Hawley rats. Ann. NY Acad. ScL (1995) 765:330–331.
   PubMedGoogle Scholar
• WILSON TCM, EISMAN MS, MACHULSKIS GE: Quantita-tion of the novel anticonvulsant remacemide in rat and dog plasma and urine: application of the plasma methodology to measure the plasma protein binding of remacemide.j Chromatogr. (1992) 582:195–202.
   PubMed Web of Science ®Google Scholar
• SCHEYER RD, CRAMER JA, LEPPIK IE et al.: Remacemideelimination after initial and chronic dosing. Clin. Pharmacol. Ther. (1992) 51:189
   Web of Science ®Google Scholar
• LOCKTON JA, BLAKEY GE, SABIN AJ, PRASAD S, WEIL A:The pharmacokinetics of the anti-convulsant drug remacemide hydrochloride in hepatic impairment. Epilepsia (1999) 40\(Suppl. 2):251.
   Google Scholar
• BLAKEY GE, LOCKTON JA, HALL DE, MANT IT: The pharmacokinetics of the anti-convulsant drug remace-mide hydrochloride in renal impairment. Epilepsia (1999) 40\(Suppl. 2):251.
   Google Scholar
• HUETTNER JE, BEAN BP: Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. ScL USA (1988) 85:1307–1311.
   PubMed Web of Science ®Google Scholar
• FOSTER AC, WONG EHF: The novel anticonvulsant MK-801 binds to the activated state of the N- methyl-D-aspartate receptor in rat brain. Br. J. Pharmacol. (1987) 91:403–409.
   PubMed Web of Science ®Google Scholar
• AHMED MS, MATHER A, ENNA SJ: Binding of [311]desglycinyl remacemide to rat brain membranes: association with the benzomorphan attachment site of the N-methyl-D-aspartic acid receptor channel. Brain Res. (1999) 827:46–50.
   PubMed Web of Science ®Google Scholar
• HU RQ, DAVIES JA: The effect of the desglycinylmetabolite of remacemide on cortical wedges prepared from DBA/2 mice. Eur. J. Pharmacol (1995) 287:251–256.
   PubMed Web of Science ®Google Scholar
• VAN LUIJTELAAR ELJM, COENEN AML: Effects of remace-mide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. Neuropharmacology (1995) 34:419–425.
   PubMed Web of Science ®Google Scholar
• NORRIS SK, KING AE: Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology (1997) 36:951–959.
   PubMed Web of Science ®Google Scholar
• DAVIES JA: Remacemide hydrochloride: a novel antiepileptic agent. Gen. Pharmacol. (1997) 28:499–502.
   PubMedGoogle Scholar
• LEACH JP, SILLS GJ, BUTLER E, FORREST G, THOMPSON GG, BRODIE MJ: Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. Br. J. Pharmacol. (1997) 121:923–926.
   PubMed Web of Science ®Google Scholar
• MCLEAN MJ, MACDONALD RL: Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J. Pharmacol. Exp. Ther. (1983) 227:779–789.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN J, RICHENS A, DAVIES JA: The effect of thedesglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endoge-nous amino acid release from mouse cortex. Br. J. Pharmacol. (1995) 116:3087–3092.
   PubMed Web of Science ®Google Scholar
• WAMIL AW, CHEUNG H, HARRIS EW, MCLEAN MJ: Remacemide HC1 and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Epilepsy Res. (1996) 23:1–14.
   PubMed Web of Science ®Google Scholar
• FRASER CM, SILLS GJ, FORREST G, THOMPSON GG, BRODIE MJ: Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br. J. Pharmacol (1999) 126:1634–1638.
   PubMed Web of Science ®Google Scholar
• HOEHN MM, YAHR MD: Parkinsonism: onset, progres-sion and mortality. Neurology (1967) 17:427–442.
   PubMed Web of Science ®Google Scholar
• ALBIN RL, YOUNG AB, PENNEY JB: The functional anatomy of basal ganglia disorders. Trends NeuroscL (1989) 12:366–375.
   PubMed Web of Science ®Google Scholar
• BERGMAN H, WICHMANN T, DELONG MR: Reversal ofexperimental parkinsonism by lesions of the subtha-lamic nucleus. Science (1990) 249:1436–1438.
   PubMed Web of Science ®Google Scholar
• MITCHELL IJ, CLARKE CE, BOYCE S et al.: Neuromecha-nisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1, 2,3, 6-tetra hydropy-ridine. Neuroscience (1989) 32:213–226.
   PubMed Web of Science ®Google Scholar
• GILL SS, HEYWOOD P: Bilateral dorsolateral subthala-motomy for advanced Parkinson's disease. Lancet (1997) 350:1222–1223.
   PubMedGoogle Scholar
• LIMOUSIN P, KRACK P, POLLAK P et al.: Electricalstimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. (1998) 339:1105–1111.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT: Pharmacologial pallidotomy with glutamate antagonists? Ann. Neurol. (1996) 39:557–558.
   Web of Science ®Google Scholar
• BROTCHIE JM, MITCHELL IJ, SANBROOK MA, CROSSMAN AR: Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. (1991) 6:133–138.
   PubMed Web of Science ®Google Scholar
• KLOCKGETHER T, TURSKI L, HONORE T et al.: The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. (1991) 30:717–723.
   PubMed Web of Science ®Google Scholar
• PAPA SM, CHASE TM: Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. (1996) 39:574–578.
   PubMed Web of Science ®Google Scholar
• ZIPP F, BAAS H, FISCHER PA: Lamotrigine-antiparkinsonian activity by blockade of glutamate release? J. Neural Transm. (1993) 5:67–75.
   Web of Science ®Google Scholar
• VERHAGEN METMAN L, DEL DOTTO P, VAN DEN MUNCKHOF P, FANG J, MOURADIAN MM, CHASE TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 50:1323–1326.
   PubMed Web of Science ®Google Scholar
• HUNTER C, JANKOVIC J: Double-blind, placebo-controlled study to assess safety and efficacy of Riluzole as a neuroprotective drug in patients with early, untreated Parkinson's disease. Neurology (1999) 52\(Suppl. 2):A214.
   Google Scholar
• GREENAMYRE JT, ELLER RV, ZHANG Z, OVADIA A, KURLAN R, GASH DM: Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. (1994) 35:655–661.
   PubMed Web of Science ®Google Scholar
• SMITH RD, ZHANG Z, KURLAN R, MCDERMOTT M, GASH DM: Developing a stable bilateral model of parkin-sonism in rhesus monkeys. Neuroscience (1993) 52:7–16.
   PubMed Web of Science ®Google Scholar
• HALONEN T, NISSINEN J, PITKANEN A: Neuroprotective effect of remacemide hydrochloride in a perforant pathway stimulation model of status epilepticus in the rat. Epilepsy Res. (1999) 34:251–269.
   PubMed Web of Science ®Google Scholar
• PALMER GC, CREGAN EC, BORRELLI AR et al.: Neuropro-tective actions of 2-amino-N-(1,2-diphenylethyl) -acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. I Pharmacol. Exp. Ther. (1995) 274:991–1000.
   PubMed Web of Science ®Google Scholar
• BANNAN PE, GRAHAM DI, LEES KR, MCCULLOCH J: Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res. (1994) 664:271–275.
   PubMed Web of Science ®Google Scholar
• PALMER GC, CLARK B, HUTCHISON JB: Antiepileptic andneuroprotective potential of remacemide hydrochlo-ride. Drugs Future (1993) 18:1021–1042.
   Google Scholar
• ZUCCARELLO M, LEWIS Al, UPPUTURI S, FARMER JB,ANDERSON DK: Effect of remacemide hydrochloride on subarachnoid hemorrhage-induced vasospasm in rabbits. J. Neurotrauma (1994) 11:691–698.
   PubMed Web of Science ®Google Scholar
• BLACK MA, TREMBLAY R, MEALING GAR, DURKIN JP,WHITFIELD JF, MORLEY P: The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons. J. Neurochem. (1996) 66:989–995.
   PubMed Web of Science ®Google Scholar
• SMITH DH, PERRI BR, RAGHUPATHI R, SAATMAN KE, MCINTOSH TK: Remacemide hydrochloride reduces cortical lesion volume following brain trauma in the rat. NeuroscL Lett. (1997) 231:135–138.
   PubMed Web of Science ®Google Scholar
• GASIOR M, UNGARD JT, WITKIN JM: Preclinical evalua-tion of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J. Pharmacol Exp. Ther. (1999) 290:1148–1156.
   PubMed Web of Science ®Google Scholar
• CRAMER CL, STAGNITTO ML, KNOWLES MA, PALMER GC: Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life ScL (1994) 541271–275.
   Google Scholar
• PALMER GC, BORRELLI AR, HUDZIK TJ, SPARBER S: Acute heat stress model of seizures in weanling rats: influence of prototypic anti-seizure compounds. Epilepsy Res. (1998) 30:203–217.
   PubMed Web of Science ®Google Scholar
• GARSKE GE, PALMER GC, NAPIER JJ et al.: Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res. (1991) 9:161–174.
   PubMed Web of Science ®Google Scholar
• STAGNITTO ML, PALMER GC, ORDY JM et al.: Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res. (1990) 7:11–28.
   PubMed Web of Science ®Google Scholar
• ALARCON G, BINNIE CD, ELWES RDC, POLKEY CE: Remacemide monotherapy in patients undergoing acute anti-epileptic drug withdrawal. Seizure (1992) (Suppl. A):7.
   Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• DIFIGLIA M: Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. (1990) 13:286–289.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K, FEIGIN A, MCDERMOTT M et al.: A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. (1996) 11:273–277.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K: Antiglutamate therapies in Huntington's disease. J. Neural Transm. (1999) 55(Suppl.):99–102.
   Google Scholar
• PARKINSON STUDY GROUP: Glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. Neurology (1999) 52 (Suppl. 2):A262.
   Google Scholar
• LANG AE, LOZANO AM: Parkinson's disease. N Engl. J.Med. (1998) 33:1044-1053, 1130–1143.
   Google Scholar
• LANG AE, FAHN S: Assessment of Parkinson's disease. In: Quantification of Neurologic Deficit. Munsat TL, (Ed.) Butterworth, Boston, USA (1989):285–309.
   Google Scholar
• CLARKE CE: A randomized, double-blind, placebo-controlled, ascending dose tolerability and safety study of remacemide as adjunct therapy to levodopa in Parkinson's disease with response fluctuations. Parkinsonism Related Disord.s (1999) 5 (Suppl.):S71.
   Google Scholar
• JONES MW, BLUME W, GUBERMAN A et al. Remacemide hydrochloride (300 mg, 600 mg, 800 mg/day): efficacy and safety versus placebo in patients with refractory epilepsy. Epilepsia (1996) 37 (Suppl. 5):166.
   Google Scholar
• MAWER GE, JAMIESON V, LUCAS SB, WILD JM: Adjust-ment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy. Epilepsia (1999) 40:190–196.
   PubMed Web of Science ®Google Scholar
• MUIR KW, LEES KR: Initial experience with remacemide hydrochloride in patients with acute ischemic stroke. Ann. NY Acad. ScL (1995) 765:322–323.
   PubMedGoogle Scholar
• ARROWSMITH JE, HARRISON MJG, NEWMAN SP, STYGALL J, TIMBERLAKE N, PUGSLEY WB: Neuroprotec-tion of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke (1998) 29:2357–2362.
   PubMed Web of Science ®Google Scholar
• GRANT KA, COLOMBO G, GRANT J, ROGAWSKI MA: Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology (1996) 35:1709–1719.
   PubMed Web of Science ®Google Scholar
• CHADWICK DW, SMITH D, BAKER G et al.: Remacemidehydrochloride: safety, tolerability and pharmacoki-netics. Epilepsia (1994) 35 (Suppl. 7):61.
   Google Scholar
• WROE S: CR 2341: an open long-term safety study ofremacemide hydrochloride (200–1200 mg/day) in medically refractory epilepsy. Epilepsia (1996) 37 (Suppl. 5) :166.
   Google Scholar
• HUDZIK TJ, PALMER GC: Effects of anticonvulsants in anovel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Epilepsy Res. (1995) 21:183–193.
   PubMed Web of Science ®Google Scholar
• LERNER RL, BURNS RS: Phencyclidine use among youth: history, epidemiology and acute and chronic intoxica-tion. NIDA Res. Monogr. (1978) 21:66–118.
   PubMedGoogle Scholar
• SLIFER BL, BALSTER RL: Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J. Pharmacol Exp. Ther. (1983) 225:522–528.
   PubMed Web of Science ®Google Scholar
• BRADY KT, WOOLVERTON WL, BALSTER RL: Discrimina-tive stimulus and reinforcing properties of etoxadrol and dexoxadrol in monkeys. J. Pharmacol. Exp. Ther. (1982) 220:56–62.
   PubMed Web of Science ®Google Scholar